The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists.

El mejor anticoagulante en fibrilación auricular post TAVI

The purpose of this paper published in JACC Interv was to compare long-term results between classic vitamin K antagonists and novel direct anticoagulant agents in patients with AF who undergo TAVR.

While this is a heterogeneous group of patients, they overall share a higher risk for events, including bleeding. The combination of AF and TAVR magnifies the difficulties of balancing the risk/benefit of different anticoagulation schemes.

The OCEAN Registry prospectively included 2588 patients who underwent TAVR, 403 of whom had AF and were discharged with anticoagulant agents.

The mean age for this population was 84.4 ± 4.7 years, with a CHA2DS2-VASc score of 5.1 ± 1.1. Patients were followed for almost 2 years, and propensity score matching was used to balance baseline characteristics.


Read also: Post MI Betablockers for Good?


The group receiving direct anticoagulant agents showed significantly lower mortality than those receiving vitamin K antagonists (10.3% vs. 23.3%; hazard ratio: 0.391; 95% confidence interval: 0.204 to 0.749; p = 0.005).

Conclusion

Direct anticoagulant agents were linked to lower mortality in patients with atrial fibrillation who underwent TAVR compared with classic vitamin K antagonists.

j-jcin-2020-09-013free

Original Title: Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR.

Reference: Hideyuki Kawashima et al. JACC Cardiovasc Interv. 2020 Nov 23;13(22):2587-2597. doi: 10.1016/j.jcin.2020.09.013.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...